Nikhil C. Munshi, MD
Adjunct Associate Professor, Medicine
Biography
Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.
A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.
Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.
Other Positions
- VA Boston Healthcare System
Education
- Maharaja Sayajirao University, MD
- Maharaja Sayajirao University, MBBS
Publications
- Published on 3/11/2025
Waldschmidt JM, Sotudeh N, Arora S, Vijaykumar T, Anand P, Stuart H, Frede J, Campbell T, Kaiser SM, Zheng X, Munshi NC, Anderson KC, Einsele H, Yee AJ, Knoechel B, Lohr JG, Raje NS. Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma. Blood Adv. 2025 Mar 11; 9(5):1132-1136. PMID: 39813623.
Read at: PubMed - Published on 2/20/2025
Bertamini L, Alberge JB, Lee DJ, El-Khoury H, Kim S, Fleming G, Murphy C, Colchie J, Davis MI, Perry J, Lightbody ED, Allam S, Goqwana LN, Philip V, Smyth N, Sakrikar D, Perkins M, Harding S, Troske D, Getz G, Karlson EW, Munshi N, Anderson KC, Trippa L, Marinac CR, Chen WC, Joffe M, Ghobrial IM. Serum free light chains in a racially diverse population including African Americans and populations from South Africa. Blood. 2025 Feb 20; 145(8):840-849. PMID: 39571144.
Read at: PubMed - Published on 2/12/2025
Shi Q, Paiva B, Pederson LD, Dimier N, Talpes E, Prior TJ, Orfao A, Moreau P, Sonneveld P, Kumar SK, Dixon JG, Patel R, Bartlett BJ, Schecter J, McCarthy P, Hose D, Seckinger A, Mattia D, Goldschmidt H, Oliva S, Owen RG, Anderson KC, San-Miguel J, Durie BGM, Munshi N. Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials. J Clin Oncol. 2025 Apr 10; 43(11):1289-1301. PMID: 39938021.
Read at: PubMed - Published on 2/1/2025
Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC. Editorial Expression of Concern: Activation of NF-?B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2025 Feb; 44(4):269. PMID: 39528816.
Read at: PubMed - Published on 1/30/2025
Samur MK, Aktas Samur A, Shah P, Park JS, Fulciniti M, Shammas M, Corre J, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC. Development of hyperdiploidy starts at an early age and takes a decade to complete. Blood. 2025 Jan 30; 145(5):520-525. PMID: 39571146.
Read at: PubMed - Published on 1/14/2025
Ferri GM, Yildirim C, Do NV, Brophy M, Park JS, Munshi NC, Fillmore NR, Edwards CV. Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma. Blood Adv. 2025 Jan 14; 9(1):78-88. PMID: 39471425.
Read at: PubMed - Published on 1/1/2025
Williams CT, Yildirim C, Dharne M, Abdallah MM, Driver JA, Munshi NC, Fillmore NR, DuMontier C. Ceiling Effect of International Myeloma Working Group Frailty Score in Real-World Population of Older Adults With Cancer. Hematol Oncol. 2025 Jan; 43(1):e70016. PMID: 39673104.
Read at: PubMed - Published on 1/1/2025
Yao Y, Deng S, Ng JF, Yuan M, Chakraborty C, JoyWeiler V, Munshi N, Fulciniti M. Unlocking the therapeutic potential of selective CDK7 and BRD4 inhibition against multiple myeloma cell growth. Haematologica. 2025 Jan 01; 110(1):153-162. PMID: 39049606.
Read at: PubMed - Published on 12/1/2024
Jiang H, Acharya C, An G, Zhong M, Feng X, Wang L, Dasilva N, Song Z, Yang G, Adrian F, Qiu L, Richardson P, Munshi NC, Tai Y-, Anderson KC. Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2024 Dec; 38(12):2739. PMID: 39438590.
Read at: PubMed - Published on 11/26/2024
Ludwig H, Munshi NC, Terpos E, Raje N, Moreau P, Nooka A. Improving reporting of infection events in clinical trials. Blood Adv. 2024 Nov 26; 8(22):5927-5928. PMID: 39110989.
Read at: PubMed
View 603 more publications: View full profile at BUMC